India CDMO Market Size, Share, Trends, Growth, Insights and Industry Report 2025-2033

According to IMARC Group's report titled "India CDMO Market Size, Share, Trends and Forecast by Service Type, Type, Scale of Operation, Therapeutic Area, and Region, 2025-2033" the report offers a comprehensive analysis of the industry, including market share, growth, trends, and regional insights.

India Cdmo Market Overview

The India CDMO market size reached USD 7.9 Billion in 2024 and is projected to reach USD 15.4 Billion by 2033, exhibiting a CAGR of 7.7% during the forecast period from 2025-2033. This growth is driven by rising demand for contract manufacturing services in pharmaceuticals, including complex generics, HPAPIs, and sterile injectables, supported by a robust regulatory framework and cost advantages.

Note: To access the most recent data, insights, and industry updates, please request a free sample report.

• Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.imarcgroup.com/india-cdmo-market/requestsample

India Cdmo Market Growth Factors

The India CDMO business is now a wide, complex and growing piece of value chain in life sciences, extending from discovery services, through formulation development and commercial manufacturing to regulatory-compliant packaging. It has also extended to specialized chemistry services, biologics and complex molecules, sterile fill/finish services and end-to-end program management, whereby sponsors have the option of outsourcing the entire program rather than discrete tasks. The resulting evolution of the supply chain is a more mature domestic supplier base that combines process expertise with growing capabilities in advanced modalities and analytical development, transforming CDMOs into value-added, trusted partners that absorb scientific risk, accelerate timelines, and unlock global market opportunities for their clients.

The growth story is supported by ecosystem factors beyond the company level, including the availability of qualified technical talent and regulatory personnel, infrastructure clusters such as life-science parks or specialized industrial zones, and an increasing degree of collaboration within the industry and with academia to feed innovation into contract services. Policy and trade factors have also played an important role in the industry's competitiveness, spurring increased capital investment and the development and adoption of quality and compliance standards. Overall, this has turned the CDMO sector into a scalable, higher-margin engine of pharmaceutical value creation, with a mix of domestic mid-sized sponsors and international innovators looking for cost-effective ways to offload pharmaceutical work.

India Cdmo Market Trends

Current trends in the India CDMO market include specialization, digitalization, and close alignment with global drug development requirements, as India CDMOs invest in dedicated infrastructure and technical capabilities for selected niche therapeutic areas and modalities and aim to become centers of excellence for specific types of therapy areas. Independently, principles of digital manufacturing and Industry Four Point Zero are reshaping the CDMO landscape. Process analytics, automation, and data-driven quality systems enable CDMOs to improve throughput, reduce variability, and provide real-time assurance to partners. Service model innovation is being driven by CDMOs moving towards outcome-based contracts, risk-sharing agreements and bundled end-to-end solutions in place of service level agreements to financially align all partners with sponsor success. Companies also are clustering in areas with favorable policies, talent pools and co-located life-science infrastructure.

This enables campus development, which can accelerate business cooperation. On the demand side, global sponsors are outsourcing higher-value work in search of efficiency and flexibility. Indian providers are additionally investing in compliance, regulatory access, and global certifications. Finally, sustainability and supply-chain resilience have become lived priorities with manufacturers revisiting their sourcing, waste and energy consumption in accordance with shifting customer expectations and regulatory changes. Together these trends show that, rather than just being a cost arbitrage destination, India is set to become a key, planned and innovation partner for global drug development and manufacturing.

India Cdmo Market Recent Developments & News

• In February 2025, Granules India acquired Swiss CDMO Senn Chemicals AG for CHF 20 Million (approx. INR 192.5 Crore), marking its entry into peptide therapeutics with access to specialized expertise in peptide synthesis and a strong European regulatory presence.
• In December 2024, Akums Drugs and Pharmaceuticals Limited entered a partnership with a global pharma company to manufacture and supply oral liquid formulations for the European market under a Euro 200 million contract set to start in 2027.

If you have any questions or need assistance, feel free to ask our expert analysts: https://www.imarcgroup.com/request?type=report&id=30719&flag=C

India Cdmo Market Segmentation

Service Type Insights:

• Contract Development Services
o Preclinical Development
o Clinical Development
o Analytical and Bioanalytical Services

• Contract Manufacturing Services
o Active Pharmaceutical Ingredients (APIs) Manufacturing
o Finished Dosage Forms (FDFs) Manufacturing
o Biologics Manufacturing
o Packaging

Type Insights:

• Small Molecules
• Biologics
• Biosimilars
• Vaccines
• Others

Scale of Operation Insights:

• Commercial Scale
• Clinical Scale

Therapeutic Area Insights:

• Oncology
• Cardiovascular Diseases
• Infectious Diseases
• Central Nervous System (CNS) Disorders
• Others

Regional Insights

• North India
• South India
• East India
• West India

India Cdmo Market Key Players

The report offers an in-depth examination of the competitive landscape, including market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant.

Discuss Your Requirements With an Analyst and Get Your Customized Market Report Now: https://www.imarcgroup.com/request?type=report&id=30719&flag=E

Key Questions Answered in This Report

Q1. How big is the India CDMO market?
A1. The India CDMO market was valued at USD 7.9 Billion in 2024.

Q2. What is the future outlook of India CDMO market?
A2. The India CDMO market is projected to exhibit a CAGR of 7.7% during 2025-2033, reaching a value of USD 15.4 Billion by 2033.

Q3. What are the key factors driving the India CDMO market?
A3. The India CDMO market is driven by increased demand from global pharmaceutical companies seeking cost-effective outsourced development and manufacturing. The country's skilled workforce, robust regulatory framework, and advanced biopharma infrastructure support complex drug development. Additionally, rising domestic R&D investments and favorable government incentives further accelerate growth and global competitiveness.

Explore More Research Reports & Get Your Free Sample Now:

India Active Pharmaceutical Ingredients Market: https://www.imarcgroup.com/india-active-pharmaceutical-ingredients-market/requestsample

India Pharmaceutical Manufacturing Market: https://www.imarcgroup.com/india-pharmaceutical-manufacturing-market/requestsample

India Online Pharmacy Market: https://www.imarcgroup.com/india-online-pharmacy-market/requestsample

India Private Healthcare Market: https://www.imarcgroup.com/india-private-healthcare-market/requestsample

India Endoscopes Market: https://www.imarcgroup.com/india-endoscopes-market/requestsample

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel: (D) +91 120 433 0800
United States: +1-201971-6302

IMARC Group is a global management consulting firm that helps ambitious changemakers create a lasting impact. The company offers comprehensive market assessment, feasibility studies, incorporation support, regulatory assistance, branding and strategy services, and procurement research.

This release was published on openPR.